SPCs demystified in our next webinar
Managing IP is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

SPCs demystified in our next webinar

Our next webinar on June 23 will discuss the latest developments regarding supplementary protection certificates (SPCs) in Europe

Drugs

The SPC regime, which dates back to 1992, has the relatively straightforward and uncontroversial purpose of extending protection for pharmaceutical (and some other) products whose launch is delayed by the regulatory process.

However, its application in practice has been complex, with many cases generating questions over the definition, scope and term of SPCs, as well as their application in different EU member states.

Continuing uncertainty

Because the regime is based on an EU Regulation, national courts have had to refer many of these questions to the Court of Justice of the EU in the hope of getting a clear ruling. Unfortunately, that hope has not always been fulfilled, leading to continuing uncertainty for many in the industry.

EU flag

Our webinar on June 23, which starts at 5pm London time, will feature Mike Gilbert and Angus Fairbairn of specialist IP firm Marks & Clerk and Dr Jocelyn Man of Gilead Sciences, and I will be moderating it.

The speakers will briefly set out the background to the SPC regime, before discussing the latest decisions from the CJEU and other open issues. These include questions such as: what does “protected by a basic patent” mean? And what is “active ingredient”? Jocelyn will also be able to provide a perspective from industry on the value of SPCs and the kinds of issues that pharma companies face.

In an industry where sales of blockbuster products can be counted in the millions of dollars per day, understanding the latest law on SPCs is vital for both originator and generic companies, so I’m sure this webinar will be of interest to all those in the industry around the world, as well as those who advise them in Europe and elsewhere.

Like all our webinars, you can easily view and listen from your desk (or anywhere with an internet connection) and there will be opportunities to ask questions of the speakers too. The webinar will last about one hour and if you can’t make next Tuesday, you can listen again at any convenient time. Registration is free, but must be done in advance.

more from across site and ros bottom lb

More from across our site

Ireland joining the UPC would offer plenty of opportunities to local attorneys but there are fears that upcoming referendum could get ‘lost in the noise’
Attorneys at four firms reveal the business opportunities that stem from patent licensing agreements in the life sciences sector
We provide a rundown of Managing IP’s news and analysis from the week, and review what’s been happening elsewhere in IP
Counsel at four firms explain their lateral hiring policies and how they retain existing lawyers
Lori Gordon, who has joined from Perkins Coie, says she hopes to turn Goodwin into a 'premier' destination for PTAB work
The LMG Life Sciences Awards is thrilled to present the shortlist for the 2024 EMEA Awards.
Partners at LeanWill Law Firm, a newly launched domestic firm in China, discuss IP opportunities and which clients they plan to target
Each week Managing IP speaks to a different IP lawyer about their life and career
A survey of more than 25,000 in-house lawyers reveals that embracing technology could help law firms win new business
John Mulgrew, vice president of IP at Lenovo, says the EU's proposed regulation will readdress imbalances in the bargaining power of SEP owners and implementers
Gift this article